BACKGROUND:    Longitudinal studies have consistently found a significant association between @entity6981 ( @entity6981 ) and acquisition of @entity2953 . However, there are limited prospective data to confirm these findings. METHODS:    We conducted a prospective, randomized, open-label trial of home screening and treatment of young @entity1 with asymptomatic @entity6981 who were also at high risk for @entity2953 . These @entity1 were screened every 2 months for 12 months and randomized to treatment with oral @entity868 500 mg twice daily for 7 days or observation alone. The primary outcome was the incidence of @entity2954 and/or @entity1047 . RESULTS:    A total of 1365 subjects were enrolled in the study across 10 sites. Adherence with mailing specimens obtained at home was excellent in both groups (84%-88%). The incidence of @entity2954 and/or @entity1047 was 19.1 per 100 @entity1 -years (95% confidence interval, 15.1-22.1) for the treatment group and 18.5 per 100 @entity1 -years (15.1-22.8) for the observation arm, a difference that was not statistically significant. CONCLUSIONS:    Young @entity1 were very amenable to home screening for @entity6981 , @entity2954 , and @entity1047 . Treatment of asymptomatic @entity6981 with 1 week of oral @entity868 did not decrease the incidence of @entity2954 and/or @entity1047 . CLINICAL TRIALS REGISTRATION:    NCT00667368.

Home Screening for XXXX to Prevent @entity2953 .

@entity1 :: ('9606', 'Species') :: ['women', 'person'] @entity2954 :: ('MESH:D006069', 'Disease') :: ['gonorrhea'] @entity868 :: ('MESH:D008795', 'Chemical') :: ['metronidazole'] @entity2953 :: ('MESH:D012749', 'Disease') :: ['sexually transmitted diseases'] @entity6981 :: ('MESH:D016585', 'Disease') :: ['BV', 'bacterial vaginosis'] @entity1047 :: ('MESH:D002690', 'Disease') :: ['chlamydia']
@entity6981 :: (MESH:D016585,Disease) :: ['Bacterial Vaginosis']
